Patients with chronic kidney disease who had hypertension and diabetes and received insulin therapy showed a 35% lower risk ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

aDepartments of Surgery, New York University, New York, NY, USA bDepartment of Medicine, New York University, New York, NY, USA ...

The gut microbiome is essential for human health and disease, acting in a symbiotic relationship with its host. In chronic kidney disease (CKD), this relationship is commonly disrupted, leading to an ...

CKD and hypertension develop more quickly and at younger ages in survivors treated for childhood cancer. Childhood cancer survivors develop hypertension and chronic kidney disease (CKD) at a ...

Strong outcomes were seen in terms of weight loss, with lower doses of semaglutide used. HealthDay News — Weight loss treatment combining personalized semaglutide with intensive behavioral therapy ...

Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used. Søren Seier, from the University of Copenhagen in Denmark, and colleagues examined the effectiveness of an ...

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...